Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03308929 · ClinicalTrials.gov registry record
Prospective G7 Dual Mobility Total Hip PMCF
A clinical trial of Survivorship and Safety, sponsored by Zimmer Biomet.
- Active
- Registry status
- 250
- Enrollment target
- 6
- Study locations
NCT03308929: Active study of Survivorship and Safety, sponsored by Zimmer Biomet.
NCT03308929 is a study of Survivorship and Safety that is active but no longer recruiting, run by Zimmer Biomet. The registered enrollment target is 250 participants, above the 223-participant average among 36 other Survivorship trials with a reported enrollment target (12% higher). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03308929, a study of Survivorship and Safety, is active but no longer recruiting, sponsored by Zimmer Biomet.
- ACTIVE NOT RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a prospective multi-center clinical evaluation following recipients of the G7 Dual Mobility hip device. The primary objective is to characterize survivorship of the G7 hip at five years post-index procedure. Secondary objectives include documentation of clinical outcomes, safety and radiographic data.
Primary Outcome
This is assessed by removal of the study device from the patient for any reason, including failure of the device, infection, or traumatic injury.
Conditions Studied
Interventions
- DEVICE G7 Dual Mobility hip
Study Locations (6)
Virginia
- Tidewater Orthopaedics - Hampton
- Ortho Virginia - Richmond
New Jersey
- Jersey City Medical Center - Jersey City
New Mexico
- New Mexico Orthopaedics - Albuquerque
North Carolina
- University of North Carolina - Chapel Hill
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2017-02-28 |
| Est. Completion | 2029-02-28 |
What the registry record for NCT03308929 still lists
NCT03308929 is an observational study that tracks outcomes without assigning an intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 223-participant average among 36 other Survivorship trials with a reported enrollment target (12% higher).
The record links to 5 conditions, with Survivorship appearing as the primary indexed condition, and to 1 intervention - of which G7 Dual Mobility hip is the first listed.
NCT03308929 lists 6 locations in 5 states (Virginia, New Jersey, New Mexico).
Frequently Asked Questions
What is clinical trial NCT03308929 about?
NCT03308929 is a clinical study titled "Prospective G7 Dual Mobility Total Hip PMCF". This is a prospective multi-center clinical evaluation following recipients of the G7 Dual Mobility hip device. The primary objective is to characterize survivorship of the G7 hip at five years post-index procedure. Secondary objectives include documentation of clinical outcomes, safety and radiogra...
What is the current status of trial NCT03308929?
This trial is currently active not recruiting. The enrollment target is 250 participants. The study started on 2017-02-28. Estimated completion is 2029-02-28.
What conditions does trial NCT03308929 study?
This clinical trial studies the following conditions: Survivorship, Safety, Clinical Outcomes, Functional Outcomes, Radiological Outcomes.
What interventions are being tested in trial NCT03308929?
The interventions under investigation include: G7 Dual Mobility hip (DEVICE).
Who is sponsoring clinical trial NCT03308929?
This trial is sponsored by Zimmer Biomet, which has 115 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03308929 being conducted?
This trial has 6 study locations across New Jersey, New Mexico, North Carolina, Oregon, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Survivorship
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03308929's enrollment target sits among peer trials
250 10th of 36 higher than 27 of 36 other Survivorship trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Survivorship trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Sleep Treatment Education Program for Cancer Survivors: STEP-Together
RECRUITING · NA
-
Dance Study for Post-surgical Pain in Breast Cancer Survivors
RECRUITING · NA
-
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
RECRUITING · Phase 2
-
Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) Multi-Site RCT
RECRUITING · NA
-
Velopharyngeal Dysfunction in Head & Neck Cancer Patients, Pilot Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI